Advertisement
Allergan
Subscribe to Allergan

The Lead

Allergan's OZURDEX® Receives European Positive Opinion for the Treatment of Diabetic Macular Edema

July 25, 2014 8:03 am | News | Comments

Allergan announced today that the European Union’s Committee for Medicinal Products for Human Use (CHMP) has recommended extending the Marketing Authorization for OZURDEX ® (dexamethasone 700 mcg intravitreal implant in applicator) to treat adult patients with vision loss due to diabetic macular edema.

Allergan Reports Second Quarter 2014 Operating Results; Announces Layoffs

July 21, 2014 8:45 am | News | Comments

Allergan, Inc. announced operating results for the quarter ended June 30, 2014 and announced a...

Valeant Takes Allergan Complaints to Regulators

July 21, 2014 8:23 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals International Inc. is complaining to regulators that Botox maker and...

Pershing Files Documents for Special Meeting Aimed at Ousting Allergan Directors

July 7, 2014 3:05 pm | by The Canadian Press | News | Comments

Pershing Square Capital Management has formally asked Allergan shareholders to support its bid...

View Sample

FREE Email Newsletter

Pershing Square Settles Lawsuit with Allergan

June 27, 2014 3:28 pm | by The Associated Press | News | Comments

Pershing Square, the investment firm run by activist investor Bill Ackman, said Friday it settled a lawsuit with Allergan, the maker of Botox, related to Allergan's poison pill plan and Pershing's $53 billion offer for the company.   

Allergan Board of Directors Rejects Unsolicited Exchange Offer from Valeant

June 23, 2014 8:23 am | News | Comments

Allergan, announced that its Board of Directors, after consultation with its independent financial and legal advisors, unanimously determined that Valeant Pharmaceuticals International, Inc.’s unsolicited exchange offer to acquire all outstanding common shares of Allergan is grossly inadequate.

Ackman Seeks Allergan 'Poison Pill' End Run

June 13, 2014 8:14 am | News | Comments

Bill Ackman's Pershing Square Capital Management, seeking legal cover in its $53 billion takeover bid for Allergan, filed a lawsuit to confirm that its push for a special meeting of shareholders won't trigger a defensive "poison pill" plan from the Botox maker.

Advertisement

Valeant Plans Hostile Bid for Allergan

June 10, 2014 5:31 pm | by Tom Murphy - AP Business Writer - Associated Press | News | Comments

Valeant Pharmaceuticals aims to take its bid for Allergan to the Botox maker's shareholders after Allegan's board unanimously rejected its latest offer of about $53 billion. Valeant said Tuesday that it looked forward to giving shareholders the opportunity "to speak for themselves" after Allergan Chairman and CEO David Pyott said that the offer wasn't worth discussing in a letter to his Valeant counterpart, Michael Pearson.

Allergan Board Unanimously Rejects Revised Unsolicited Proposal from Valeant

June 10, 2014 8:33 am | News | Comments

Allergan announced that its Board of Directors has unanimously determined that the revised unsolicited proposal from Valeant Pharmaceuticals substantially undervalues the company, creates significant risks and uncertainties for the stockholders of Allergan, and is not in the best interests of the company and its stockholders.

Allergan Tops 2014 Newsweek Green Rankings

June 5, 2014 8:13 am | News | Comments

The Newsweek Green Rankings evaluate the world's largest publicly traded companies using eight metrics that collectively provide a transparent measurement of overall corporate environmental performance. Companies were scored on each metric against their industry peers using a 0-100% scale.

Proxy Fight Looms in Allergan-Valeant Dispute

June 2, 2014 3:42 pm | News | Comments

Activist investor Bill Ackman said Monday that he will move to replace most of Allergan's board of directors as part of a continuing battle for control of the company.              

Valeant Sweetens Offer for Allergan Again

May 30, 2014 4:01 pm | by ALEX VEIGA, AP Business Writer | News | Comments

Valeant Pharmaceuticals is sweetening its offer to buy Botox maker Allergan for the second time this week. The Canadian drugmaker said Friday it is now offering $72 and a portion of its stock for each Allergan share.      

Advertisement

Valeant Raises Cash-Stock Offer for Allergan

May 28, 2014 7:29 am | by The Associated Press | News | Comments

Valeant Pharmaceuticals is adding more cash to its offer to buy Botox maker Allergan in a bid that could now be worth more than $49 billion. The Canadian drugmaker says it will now offer $58.30 and a portion of its stock for each Allergan share.

Valeant to Improve its Hostile Takeover Bid for Allergan

May 13, 2014 9:45 am | by The Canadian Press | News | Comments

Valeant Pharmaceuticals International says it will improve its bid of almost $47 billion for Botox-maker Allergan after the company rejected its hostile takeover offer. Valeant CEO Michael Pearson says the company is prepared to pay a fair price, but will remain financially disciplined when it makes its new offer later this month.

Allergan Board Turns Down Valeant Takeover Offer

May 12, 2014 8:17 am | News | Comments

Allergan spurned a takeover bid from Valeant Pharmaceuticals, saying that the unsolicited offer worth nearly $46 billion undervalues the company and carries significant risk.                     

Allergan Lifts 2014 Outlook After First Quarter Income Rises

May 7, 2014 11:31 am | by The Associated Press | News | Comments

Botox maker Allergan raised its outlook for the year Wednesday after topping expectations for the first quarter. Executives did not discuss a $45.6 billion offer last month from Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman to buy the company, but did reiterate that that the proposal is under review.

Valeant Could Be Pushed to Boost Allergan Price By Up to 40%: Analyst

April 29, 2014 8:19 am | by Ross Marowits, The Canadian Press | News | Comments

Valeant Pharmaceuticals International could be pushed to increase the cash component of its bid for Botox maker Allergan by up to 40 per cent, an industry analyst said Monday.             

Advertisement

Valeant to Replace Three Board Members; Allergan Adopts Poison Pill Defense

April 23, 2014 2:24 pm | by Ross Marowits, The Canadian Press | News | Comments

Valeant Pharmaceuticals International says three of its directors will not stand for re-election this year as it pursues the acquisition of Botox maker Allergan, which has adopted a "poison pill" defense while it considers the offer.   

Valeant, Ackman Bid For Maker of Botox

April 23, 2014 8:37 am | Videos | Comments

WSJ discusses the Ackman/Valeant deal for Allergan.                                  

Investor Pressure Pushing Pharmaceutical M&A Deals

April 22, 2014 7:31 pm | by Linda A. Johnson - AP Business Writer - Associated Press | News | Comments

Drugmakers eager to satisfy shareholders by boosting profits and share prices are wheeling, dealing and in one case even making trades like a pro sports team looking to shake up its roster. The moves could spur more mergers and acquisitions in the industry.

Allergan Draws Bid from Valeant

April 22, 2014 12:29 am | by Ken Sweet - AP Business Writers - Associated Press | News | Comments

Valeant said Monday that it intends to propose a merger with Allergan using a combination of Valeant stock and cash. The transaction size has not been disclosed, but Valeant expects the cash portion of the deal to be at least $15 billion.   

Allergan to Sell Lap-Band Unit for $75M in cash

October 29, 2013 1:21 pm | News | Comments

Allergan reported better-than-expected earnings Wednesday and announced it is selling its Lap-Band gastric bypass business. Apollo Endosurgery will give Allergan an upfront payment of $75 million in cash plus a $15 million stake in the company in return for rights to the device, which is a stomach-restricting band used to treat obesity.

FDA Approves Botox for Crow's Feet

September 11, 2013 1:43 pm | by The Associated Press | News | Comments

U.S. government regulators for the first time have approved Botox injections to treat crow's feet. The Food and Drug Administration said Wednesday that Allergan's Botox Cosmetic injection is the first drug approved to treat the wrinkles that form on the outside edge of the eyes. Allergan studied...

Allergan Shares Up Slightly a Day after Steep Drop

June 26, 2013 7:59 am | News | Comments

Shares of Allergan rebounded slightly Tuesday, a day after dropping by double digits on news that a generic version of one of its key drugs might face an easier-than-expected path for getting regulatory approval. The FDA said Friday that a generic version of Restasis could be accepted for approval without a requirement for testing in humans, essentially if the drug's composition is similar enough to Allergan's Restasis eye treatment.

Allergan Slides After FDA Issues Guidance

June 25, 2013 7:58 am | by The Associated Press | News | Comments

Shares of drug developer Allergan Inc. sank Monday on the first full trading day after the Food and Drug Administration released a draft of guidance that could provide an easier-than-expected path to approval for a generic challenger to its eye treatment Restasis.

Allergan Names Douglas Ingram as President

June 24, 2013 6:09 pm | by The Associated Press | News | Comments

Allergan Inc. said Monday that it has named Douglas Ingram as president of the pharmaceutical and medical device company. In the newly created position, Ingram will be responsible for leading the company's global commercial operations, which includes Botox and Juvederm facial filler brands. ...

Allergan shares Fall on Delay of Eye Drug Study

May 1, 2013 2:51 pm | by The Associated Press | News | Comments

Shares of cosmetic drug and device maker Allergan Inc. fell 12 percent Wednesday after company executives said they would delay late-stage testing of an experimental eye treatment by one to two years. Allergan was previously expected to launch a study of DARP-in, an experimental drug for macular...

Allergan Says FDA Wants More Info on Migraine Drug

April 16, 2013 11:42 am | News | Comments

Allergan said the FDA is concerned about elements of the manufacturing process for Levadex. The company said it is already responding to those concerns because the FDA had identified them in previous discussions. In March 2012, the FDA said it could not approve Levadex until the concerns related to manufacturing and other issues were addressed.

Novel Amgen Virus-Vaccine Shrinks Melanoma Tumors

March 20, 2013 4:34 pm | by LINDA A. JOHNSON - AP Business Writer - Associated Press | News | Comments

Shares of drugmaker Amgen Inc. climbed Wednesday on news that its innovative melanoma drug, which uses a virus as a Trojan horse to infiltrate and destroy tumors, shrank far more tumors than a standard treatment in a late-stage test. The partial study results, released late Tuesday, show promise...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading